C. Leur, au moment de l'échec virologique, était en moyenne de 155 ± 123 copies/ml (Minimum : 45 -Maximum 391)

F. Cazein, F. Lot, J. Pillonel, L. Strat, Y. Sommen et al., Découvertes de séropositivité VIH et sida -France, pp.9-10154, 2003.

T. Le, E. Wright, D. Smith, W. He, G. Catano et al., Enhanced CD4+ T-Cell Recovery with Earlier HIV-1 Antiretroviral Therapy, New England Journal of Medicine, vol.368, issue.3, pp.218-230, 2013.
DOI : 10.1056/NEJMoa1110187

V. Supervie, J. Ndawinz, S. Lodi, and D. Costagliola, The undiagnosed HIV epidemic in

F. Barré-sinoussi, The early years of HIV research: integrating clinical and basic research, Nature Medicine, vol.9, issue.7
DOI : 10.1038/nm0703-844

A. Seelamgari, A. Maddukuri, R. Berro, C. De-la-fuente, K. Kehn et al., Role of viral regulatory and accessory proteins in HIV-1 replication, Frontiers in Bioscience, vol.9, issue.1-3, pp.2388-2413, 2004.
DOI : 10.2741/1403

L. Mansky and H. Temin, Lower in vivo mutation rate of human immunodeficiency virus type 1 than that predicted from the fidelity of purified reverse transcriptase, Journal of virology, issue.8, pp.695087-5094, 1995.

A. Jetzt, H. Yu, G. Klarmann, R. Y. Preston, B. Dougherty et al., High Rate of Recombination throughout the Human Immunodeficiency Virus Type 1 Genome, Journal of Virology, vol.74, issue.3, pp.1234-1240, 2000.
DOI : 10.1128/JVI.74.3.1234-1240.2000

R. Hoetelmans, Sanctuary sites in HIV-1 infection, Antiviral therapy, vol.3, issue.4, pp.13-17, 1998.

J. Plantier, M. Leoz, J. Dickerson, D. Oliveira, F. Cordonnier et al., A new human immunodeficiency virus derived from gorillas, Nature Medicine, vol.24, issue.8, pp.871-872, 2009.
DOI : 10.1038/nm.2016

A. Kandathil, S. Ramalingam, R. Kannangai, S. David, and G. Sridharan, Molecular epidemiology of HIV. The Indian journal of medical research, pp.333-344, 2005.

F. Mccutchan, Global epidemiology of HIV, Journal of Medical Virology, vol.20, issue.S1, pp.7-12, 2006.
DOI : 10.1002/jmv.20599

A. Vessière, D. Rousset, A. Kfutwah, M. Leoz, A. Depatureaux et al., Diagnosis and Monitoring of HIV-1 Group O-Infected Patients in Cameroun, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.53, issue.1, pp.107-110, 2010.
DOI : 10.1097/QAI.0b013e3181b97ec1

A. Vallari, V. Holzmayer, B. Harris, J. Yamaguchi, C. Ngansop et al., Confirmation of Putative HIV-1 Group P in Cameroon, Journal of Virology, vol.85, issue.3, pp.1403-1407, 2011.
DOI : 10.1128/JVI.02005-10

P. Bieniasz, An overview of intracellular interactions between immunodeficiency viruses and their hosts, AIDS, vol.26, issue.10, pp.1243-1254
DOI : 10.1097/QAD.0b013e328353bd04

B. Friedrich, N. Dziuba, G. Li, M. Endsley, J. Murray et al., Host factors mediating HIV-1 replication. Virus research, pp.101-114, 2011.
DOI : 10.1016/j.virusres.2011.08.001

S. Goff, Host factors exploited by retroviruses, Nature Reviews Microbiology, vol.100, issue.4, pp.253-263, 2007.
DOI : 10.1038/nrmicro1541

N. Arhel, B. Van-maele, K. Busschots, L. Vandekerckhove, F. Christ et al., Revisiting HIV-1 uncoating, Retrovirology, vol.7, issue.1, pp.96-122, 2006.
DOI : 10.1186/1742-4690-7-96

URL : http://doi.org/10.1186/1742-4690-7-96

E. Clark, HIV: Dendritic cells as embers for the infectious fire, Current Biology, vol.6, issue.6, pp.655-657, 1996.
DOI : 10.1016/S0960-9822(09)00441-2

C. Semaille, F. Lot, J. Pillonel, and F. Cazein, Épidémiologie, transmission et prévention de l'infection à VIH. EMC -Maladies infectieuses, pp.1-10, 2011.

S. Lang, M. Mary-krause, L. Cotte, J. Gilquin, M. Partisani et al., Increased risk of myocardial infarction in HIV-infected patients in France, relative to the general population, AIDS, vol.24, issue.8, pp.241228-1230
DOI : 10.1097/QAD.0b013e328339192f

P. Morlat, A. Vivot, M. Vandenhende, F. Dauchy, J. Asselineau et al., Role of traditional risk factors and antiretroviral drugs in the incidence of chronic kidney disease, PloS One, vol.8, issue.6, pp.2004-2012, 2013.
URL : https://hal.archives-ouvertes.fr/hal-01101114

E. Lanoy, J. Spano, F. Bonnet, M. Guiguet, F. Boué et al., The spectrum of malignancies in HIV-infected patients in 2006 in France: The ONCOVIH study, International Journal of Cancer, vol.45, issue.2, pp.467-475, 2011.
DOI : 10.1002/ijc.25903

F. Bonnet, H. Amieva, F. Marquant, C. Bernard, M. Bruyand et al., Cognitive disorders in HIV-infected patients, AIDS, vol.27, issue.3, pp.391-400
DOI : 10.1097/QAD.0b013e32835b1019

URL : https://hal.archives-ouvertes.fr/hal-01101101

P. Morlat, C. Roussillon, S. Henard, D. Salmon, F. Bonnet et al., Causes of death among HIV-infected patients in France in 2010 (national survey), AIDS, vol.28, issue.8, pp.281181-1191, 2000.
DOI : 10.1097/QAD.0000000000000222

B. Branson, The Future of HIV Testing, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.55, issue.2, pp.102-107, 2010.
DOI : 10.1097/QAI.0b013e3181fbca44

T. Ly, S. Laperche, C. Brennan, A. Vallari, A. Ebel et al., Evaluation of the sensitivity and specificity of six HIV combined p24 antigen and antibody assays, Journal of Virological Methods, vol.122, issue.2, pp.185-194, 2004.
DOI : 10.1016/j.jviromet.2004.08.018

D. Costagliola, F. Damond, P. Palmer, C. Rouzioux, F. Brun-vezinet et al., One or two enzymelinked immunosorbent assay tests on the first serum sample for initial diagnosis of HIV-1 infection? AIDS Performances of four fourthgeneration human immunodeficiency virus-1 screening assays, Journal of medical virology, vol.22, issue.8412, pp.2042-20441884, 2008.

M. Pandori, J. Hackett, B. Louie, A. Vallari, T. Dowling et al., Assessment of the ability of a fourth-generation immunoassay for human immunodeficiency virus (HIV) antibody and p24 antigen to detect both acute and recent HIV infections in a high-risk setting AIDS: proposed WHO criteria for interpreting western blot assays for HIV-1, HIV-2, and HTLV-I/HTLV-II. Bulletin of the World Health Organization, Journal of clinical microbiology, vol.40, issue.691, pp.472639-2642127, 1991.

H. Autorité and D. Santé, infection due au VIH chez les sujets âgés de plus de 18 mois (à l'exclusion du dépistage sur les dons de sang et chez les donneurs d'organes ou de tissus) http://www.has-sante.fr/portail/jcms/c_271991/fr/strategies-du-diagnostic-biologique-de-l- infection-due-au-vih-chez-les-sujets-ages-de-plus-de-18-mois-a-l-exclusion

H. Autorité-de-santé-dépistage-de-l-'infection-par-le-vih-en-france, has-sante.fr/portail/jcms/c_866949/fr/depistage-de-linfection-par-le-vih-en-france- strategies-et-dispositif-de-depistage?xtmc=&xtcr=1 43 Arrêté du 28 mai 2010 fixant les conditions de réalisation du diagnostic biologique de l'infection à virus de l'immunodéficience humaine (VIH 1 et 2) et les conditions de réalisation du test rapide d'orientation diagnostique dans les situations d'urgence http

C. Normandie, Surveillance VIH -Sida Région Haute-Normandie, Point Épidémiologique, vol.2012, pp.1-4

K. Champenois, L. Vu, S. Cuzin, L. Semaille, C. Yazdanpanah et al., Factors associated with acute HIV infection diagnosis in MSM, ANRS-Opportunity study, PloS One, vol.2012, issue.72, pp.31695-31742, 2013.

D. Jong, M. Hulsebosch, H. Lange, J. De-saussure, P. Saurat et al., Clinical, virological and immunological features of primary HIV-1 infection. Genitourinary medicine Symptomatic primary infection due to human immunodeficiency virus type 1: review of 31, pp.367-373, 1991.

J. Routy, P. Vanhems, D. Rouleau, C. Tsoukas, E. Lefèbvre et al., Comparison of Clinical Features of Acute HIV-1 Infection in Patients Infected Sexually or Through Injection Drug Use, JAIDS Journal of Acquired Immune Deficiency Syndromes, vol.24, issue.5, pp.425-432, 2000.
DOI : 10.1097/00126334-200008150-00004

D. Cooper, J. Gold, P. Maclean, B. Donovan, R. Finlayson et al., Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion, Lancet, vol.1, issue.8428, pp.537-540, 1985.
DOI : 10.1016/s0140-6736(85)91205-x

H. Gaines, M. Von-sydow, P. Pehrson, and P. Lundbegh, Clinical picture of primary HIV infection presenting as a glandular-fever-like illness., BMJ, vol.297, issue.6660, pp.2971363-1368, 1988.
DOI : 10.1136/bmj.297.6660.1363

H. Kessler, B. Blaauw, J. Spear, D. Paul, L. Falk et al., Diagnosis of Human Immunodeficiency Virus Infection in Seronegative Homosexuals Presenting With an Acute Viral Syndrome, JAMA: The Journal of the American Medical Association, vol.258, issue.9, pp.1196-1199, 1987.
DOI : 10.1001/jama.1987.03400090080038

M. Weinert, R. Grimes, and D. Lynch, Oral manifestations of HIV infection. Annals of internal medicine, pp.485-496, 1996.

C. Decker, R. Tiernan, S. Paparello, L. Hagberg, B. Malmvall et al., Esophageal candidiasis associated with acute infection due to human immunodeficiency virus Clinical infectious diseases : an official publication of the Infectious Diseases Society of America Guillain-Barré syndrome as an early manifestation of HIV central nervous system infection. Scandinavian journal of infectious diseases, pp.791-59, 1986.

F. Boufassa, C. Bachmeyer, N. Carré, C. Deveau, A. Persoz et al., Influence of neurologic manifestations of primary human immunodeficiency virus infection on disease progression. SEROCO Study Group. The Journal of infectious diseases, pp.1711190-1195, 1995.

D. Denning, J. Anderson, P. Rudge, and H. Smith, Acute myelopathy associated with primary infection with human immunodeficiency virus., BMJ, vol.294, issue.6565, pp.143-144, 1987.
DOI : 10.1136/bmj.294.6565.143

D. Cooper, B. Tindall, E. Wilson, A. Imrie, and R. Penny, Characterization of T lymphocyte responses during primary infection with human immunodeficiency virus. The Journal of infectious diseases, pp.889-896, 1988.

H. Gaines, V. Sydow, M. , V. Stedingk, L. Biberfeld et al., Immunological changes in primary HIV-1 infection, AIDS, vol.4, issue.10, pp.995-999, 1990.
DOI : 10.1097/00002030-199010000-00008

J. Zaunders, A. Carr, L. Mcnally, R. Penny, and D. Cooper, Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes, AIDS, vol.9, issue.6, pp.561-566, 1995.
DOI : 10.1097/00002030-199506000-00005

H. Lane, H. Masur, E. Gelmann, D. Longo, R. Steis et al., Correlation between immunologic function and clinical subpopulations of patients with the acquired immune deficiency syndrome. The American journal of medicine Risk of developing AIDS after primary acute HIV-1 infection, Journal of acquired immune deficiency syndromes, vol.78, issue.66, pp.417-422575, 1985.

S. Lindbäck, C. Broström, A. Karlsson, and H. Gaines, Does symptomatic primary HIV-1

M. Cohen, G. Shaw, A. Mcmichael, and B. Haynes, Acute HIV-1 Infection, New England Journal of Medicine, vol.364, issue.20, pp.1943-1954, 2011.
DOI : 10.1056/NEJMra1011874

C. Miller, Q. Li, K. Abel, E. Kim, Z. Ma et al., Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus, Journal of virology, issue.14, pp.799217-9227, 2005.

Z. Zhang, T. Schuler, M. Zupancic, S. Wietgrefe, K. Staskus et al., Sexual Transmission and Propagation of SIV and HIV in Resting and Activated CD4+ T Cells, Science, vol.286, issue.5443, pp.1353-1357, 1999.
DOI : 10.1126/science.286.5443.1353

Q. Li, P. Skinner, S. Ha, L. Duan, T. Mattila et al., Visualizing Antigen-Specific and Infected Cells in Situ Predicts Outcomes in Early Viral Infection, Science, vol.323, issue.5922, pp.3231726-1729, 2009.
DOI : 10.1126/science.1168676

S. Galvin and M. Cohen, The role of sexually transmitted diseases in HIV transmission, Nature Reviews Microbiology, vol.14, issue.1
DOI : 10.1097/00007435-200003000-00004

M. Bomsel, Transcytosis of infectious human immunodeficiency virus across a tight human epithelial cell line barrier, Nature Medicine, vol.98, issue.1, pp.42-47, 1997.
DOI : 10.1083/jcb.113.2.275

G. Apodaca, Endocytic Traffic in Polarized Epithelial Cells: Role of the Actin and Microtubule Cytoskeleton, Traffic, vol.1, issue.3, pp.149-159, 2001.
DOI : 10.1034/j.1600-0854.2001.020301.x

T. Geijtenbeek, D. Kwon, R. Torensma, S. Van-vliet, G. Van-duijnhoven et al., DC-SIGN, a Dendritic Cell???Specific HIV-1-Binding Protein that Enhances trans-Infection of T Cells, Cell, vol.100, issue.5, pp.587-597, 2000.
DOI : 10.1016/S0092-8674(00)80694-7

F. Baribaud, S. Pöhlmann, and R. Doms, The Role of DC-SIGN and DC-SIGNR in HIV and SIV Attachment, Infection, and Transmission, Virology, vol.286, issue.1, pp.1-6, 2001.
DOI : 10.1006/viro.2001.0975

J. Hu, M. Gardner, and C. Miller, Simian Immunodeficiency Virus Rapidly Penetrates the Cervicovaginal Mucosa after Intravaginal Inoculation and Infects Intraepithelial Dendritic Cells, Journal of Virology, vol.74, issue.13, pp.746087-6095, 2000.
DOI : 10.1128/JVI.74.13.6087-6095.2000

A. Haase, Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annual review of medicine, pp.127-139, 2011.

A. Mcmichael, P. Borrow, G. Tomaras, N. Goonetilleke, and B. Haynes, The immune response during acute HIV-1 infection: clues for vaccine development, Nature Reviews Immunology, vol.9, issue.1, pp.11-23, 2010.
DOI : 10.1038/nri2674

J. Mattapallil, D. Douek, B. Hill, Y. Nishimura, M. Martin et al., Massive infection and loss of memory CD4+ T cells in multiple tissues during acute SIV infection, Nature, vol.82, issue.7037, pp.4341093-1097, 2005.
DOI : 10.1084/jem.164.1.280

A. Stacey, P. Norris, L. Qin, E. Haygreen, E. Taylor et al., Induction of a Striking Systemic Cytokine Cascade prior to Peak Viremia in Acute Human Immunodeficiency Virus Type 1 Infection, in Contrast to More Modest and Delayed Responses in Acute Hepatitis B and C Virus Infections, Journal of Virology, vol.83, issue.8, pp.833719-3733, 2009.
DOI : 10.1128/JVI.01844-08

B. Malleret, B. Manéglier, I. Karlsson, P. Lebon, M. Nascimbeni et al., Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression, Blood, vol.112, issue.12, pp.1124598-4608, 2008.
DOI : 10.1182/blood-2008-06-162651

URL : https://hal.archives-ouvertes.fr/hal-00345337

G. Alter, N. Teigen, R. Ahern, H. Streeck, A. Meier et al., Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. The Journal of infectious diseases, pp.1951452-1460, 2007.

P. Borrow and N. Bhardwaj, Innate immune responses in primary HIV-1 infection. Current opinion in HIV and AIDS, pp.36-44, 2008.

J. Ward, M. Bonaparte, J. Sacks, J. Guterman, M. Fogli et al., HIV modulates the expression of ligands important in triggering natural killer cell cytotoxic responses on infected primary T-cell blasts, Blood, vol.110, issue.4, pp.1207-1214, 2007.
DOI : 10.1182/blood-2006-06-028175

D. Richman, T. Wrin, S. Little, and C. Petropoulos, Rapid evolution of the neutralizing antibody response to HIV type 1 infection, Proceedings of the National Academy of Sciences, vol.100, issue.7, pp.4144-4149, 2003.
DOI : 10.1073/pnas.0630530100

E. Gray, P. Moore, I. Choge, J. Decker, F. Bibollet-ruche et al., Neutralizing Antibody Responses in Acute Human Immunodeficiency Virus Type 1 Subtype C Infection, Journal of Virology, vol.81, issue.12, pp.816187-6196, 2007.
DOI : 10.1128/JVI.00239-07

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1900112

S. Jung, D. Unutmaz, P. Wong, G. Sano, K. De-los-santos et al., In Vivo Depletion of CD11c+ Dendritic Cells Abrogates Priming of CD8+ T Cells by Exogenous Cell-Associated Antigens, Immunity, vol.17, issue.2, pp.211-220, 2002.
DOI : 10.1016/S1074-7613(02)00365-5

T. Chun, L. Carruth, D. Finzi, X. Shen, J. Digiuseppe et al., Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection, Nature, vol.387, issue.6629, pp.387183-188, 1997.
DOI : 10.1038/387183a0

J. Blankson, D. Persaud, and R. Siliciano, The Challenge of Viral Reservoirs in Hiv

S. Eriksson, E. Graf, V. Dahl, M. Strain, S. Yukl et al., Comparative Analysis of Measures of Viral Reservoirs in HIV-1 Eradication Studies, PLoS Pathogens, vol.108, issue.2, p.1003174
DOI : 10.1371/journal.ppat.1003174.t004

A. Mclean and C. Michie, In vivo estimates of division and death rates of human T lymphocytes., Proceedings of the National Academy of Sciences, vol.92, issue.9, pp.3707-3711, 1995.
DOI : 10.1073/pnas.92.9.3707

T. Chun, D. Finzi, J. Margolick, K. Chadwick, D. Schwartz et al., In vivo fate of HIV-1-infected T cells: Quantitative analysis of the transition to stable latency, Nature Medicine, vol.4, issue.12, pp.1284-1290, 1995.
DOI : 10.1038/373117a0

T. Chun, D. Engel, S. Mizell, L. Ehler, and A. Fauci, Induction of HIV-1 Replication in Latently Infected CD4+ T Cells Using a Combination of Cytokines. The Journal of experimental medicine, p.83, 1998.

N. Ngo-giang-huong, C. Deveau, D. Silva, I. Pellegrin, I. Venet et al., Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy, AIDS, vol.15, issue.6, pp.15665-673, 2001.
DOI : 10.1097/00002030-200104130-00001

N. Chomont, M. El-far, P. Ancuta, L. Trautmann, F. Procopio et al., HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation, Nature Medicine, vol.45, issue.8, pp.15893-900, 2009.
DOI : 10.1038/nm.1972

J. Embretson, M. Zupancic, J. Ribas, A. Burke, P. Racz et al., Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS, Nature, vol.362, issue.6418, pp.362359-362, 1993.
DOI : 10.1038/362359a0

D. Mcilroy, B. Autran, R. Cheynier, S. Wain-hobson, J. Clauvel et al., Infection frequency of dendritic cells and CD4+ T lymphocytes in spleens of human immunodeficiency virus-positive patients, Journal of virology, issue.8, p.694737, 1995.

S. Mehandru, M. Poles, K. Tenner-racz, V. Manuelli, P. Jean-pierre et al., Mechanisms of Gastrointestinal CD4+ T-Cell Depletion during Acute and Early Human Immunodeficiency Virus Type 1 Infection, Journal of Virology, vol.81, issue.2, pp.599-612, 2007.
DOI : 10.1128/JVI.01739-06

J. Estes, L. Harris, N. Klatt, T. B. Pittaluga, S. Paiardini et al., Damaged Intestinal Epithelial Integrity Linked to Microbial Translocation in Pathogenic Simian Immunodeficiency Virus Infections, PLoS Pathogens, vol.434, issue.8, p.1001052, 2010.
DOI : 10.1371/journal.ppat.1001052.s011

F. Scaravilli, C. Bazille, and F. Gray, Neuropathologic Contributions to Understanding AIDS and the Central Nervous System, Brain Pathology, vol.2, issue.2, pp.197-208, 2007.
DOI : 10.1002/ana.410200316

C. Rouzioux, J. Hubert, M. Burgard, C. Deveau, C. Goujard et al., Early levels of HIV-1 DNA in peripheral blood mononuclear cells are predictive of disease progression independently of HIV-1 RNA levels and CD4+ T cell counts. The Journal of infectious diseases, pp.46-55, 2005.

V. Avettand-fènoël, F. Boufassa, J. Galimand, L. Meyer, C. Rouzioux et al., HIV-1 DNA for the measurement of the HIV reservoir is predictive of disease progression in seroconverters whatever the mode of result expression is Journal of clinical virology: the official publication of the Pan American Society for Clinical Virology, pp.399-404, 2008.

C. Goujard, M. Bonarek, L. Meyer, F. Bonnet, M. Chaix et al., CD4 cell count and HIV DNA level are independent predictors of disease progression after primary HIV type 1

B. Descours, V. Avettand-fènoël, C. Blanc, A. Samri, A. Mélard et al., Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, pp.541495-1503, 2012.

K. Poropatich and D. Sullivan, Human immunodeficiency virus type 1 long-term nonprogressors: the viral, genetic and immunological basis for disease non-progression. The Journal of general virology, pp.92247-268, 2011.

A. Sáez-cirión, C. Bacchus, L. Hocqueloux, V. Avettand-fènoël, I. Girault et al., Post-Treatment HIV-1 Controllers with a Long-Term Virological Remission after the Interruption of Early Initiated Antiretroviral Therapy ANRS VISCONTI Study, PLoS Pathogens, vol.22, issue.16, p.1003211
DOI : 10.1371/journal.ppat.1003211.s007

M. Cohen, Y. Chen, M. Mccauley, T. Gamble, M. Hosseinipour et al., Prevention of HIV-1 Infection with Early Antiretroviral Therapy, New England Journal of Medicine, vol.365, issue.6, pp.365493-505, 2011.
DOI : 10.1056/NEJMoa1105243

C. European and . Society, Guidelines Version 7.0, 2013.

H. Günthard, J. Aberg, J. Eron, J. Hoy, A. Telenti et al., Antiretroviral Treatment of Adult HIV Infection, JAMA, vol.312, issue.4, pp.312410-425
DOI : 10.1001/jama.2014.8722

S. Kinloch-de-loës, B. Hirschel, B. Hoen, D. Cooper, B. Tindall et al., A Controlled Trial of Zidovudine in Primary Human Immunodeficiency Virus Infection, New England Journal of Medicine, vol.333, issue.7, pp.333408-413, 1995.
DOI : 10.1056/NEJM199508173330702

M. Niu, J. Bethel, M. Holodniy, H. Standiford, and S. Schnittman, Zidovudine Treatment in Patients with Primary (Acute) Human Immunodeficiency Virus Type 1 Infection: A Randomized, Double-Blind, Placebo-Controlled Trial, Journal of Infectious Diseases, vol.178, issue.1, pp.80-91, 1998.
DOI : 10.1086/515612

L. Perrin, S. Yerly, A. Lazzarin, G. Tambussi, P. Hermans et al., Reduced viremia and increased CD4/CD8 ratio in patients with primary HIV infection treated with AZTddI, 1996.

A. Saimot, A triple nucleoside analogue combination in four patient with primary HIV-1

A. Lafeuillade, C. Poggi, C. Tamalet, N. Profizi, C. Tourres et al., Effects of a combination of zidovudine, didanosine, and lamivudine on primary human immunodeficiency virus type 1 infection. The Journal of infectious diseases, pp.1051-1055, 1997.

M. Markowitz, Y. Cao, and A. Hurley, Triple therapy with AZT, 3TC and ritonavir in 12 subjects newly infected with HIV-1. Abstract ThB933, Eleventh International Conference on AIDS, 1996.

M. Berrey, T. Schacker, A. Collier, T. Shea, S. Brodie et al., Treatment of Primary Human Immunodeficiency Virus Type 1 Infection with Potent Antiretroviral Therapy Reduces Frequency of Rapid Progression to AIDS, The Journal of Infectious Diseases, vol.183, issue.10, pp.1831466-1475, 2001.
DOI : 10.1086/320189

H. Streeck, H. Jessen, G. Alter, N. Teigen, M. Waring et al., Immunological and virological impact of highly active antiretroviral therapy initiated during acute HIV-1 infection. The Journal of infectious diseases, pp.734-739, 2006.

C. Hogan, V. Degruttola, X. Sun, S. Fiscus, D. Rio et al., The Setpoint Study (ACTG A5217): Effect of Immediate Versus Deferred Antiretroviral Therapy on Virologic Set Point in Recently HIV-1-Infected Individuals, Journal of Infectious Diseases, vol.205, issue.1, pp.87-96
DOI : 10.1093/infdis/jir699

B. Hoen, D. Cooper, F. Lampe, L. Perrin, N. Clumeck et al., Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, pp.45381-390, 2007.
URL : https://hal.archives-ouvertes.fr/hal-00465353

. Spartac-trial-investigators, S. Fidler, K. Porter, F. Ewings, J. Frater et al., Short-Course Antiretroviral Therapy in Primary HIV Infection, New England Journal of Medicine, vol.368, issue.3, pp.207-217, 2013.
DOI : 10.1056/NEJMoa1110039

B. Jung, N. Rezk, A. Bridges, A. Corbett, and A. Kashuba, Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography???tandem mass spectrometry, Biomedical Chromatography, vol.328, issue.10, pp.1095-1104, 2007.
DOI : 10.1002/bmc.865

M. Chaix, R. Seng, P. Frange, L. Tran, V. Avettand-fenoël et al., Increasing HIV- 1 non-B subtype primary infections in patients in France and effect of HIV subtypes on virological and immunological responses to combined antiretroviral therapy. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, pp.56880-887, 2013.

D. Descamps, P. Flandre, V. Calvez, G. Peytavin, V. Meiffredy et al., Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of inductionmaintenance therapy, Trilège

A. Cheret, G. Nembot, and A. Melard, The optiprim-ANRS 147 trial Group. Paradoxical impact of maraviroc/raltegravir added to HAART in acute HIV infection: ANRS 147 trial, Conférence on Retroviruses and Opportunistic Infections, 2014.

/. Abacavir, emtricitabine as part of combination regimens for initial treatment of HIV: final results.The Journal of infectious diseases, pp.1191-1201, 2011.

K. Smith, P. Patel, D. Fine, N. Bellos, L. Sloan et al., Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment, AIDS, vol.23, issue.12, pp.1547-1556, 2009.
DOI : 10.1097/QAD.0b013e32832cbcc2

J. Gallant, E. Dejesus, J. Arribas, A. Pozniak, B. Gazzard et al., Tenofovir DF, Emtricitabine, and Efavirenz vs. Zidovudine, Lamivudine, and Efavirenz for HIV, New England Journal of Medicine, vol.354, issue.3, pp.251-260, 2006.
DOI : 10.1056/NEJMoa051871

J. Molina, J. Andrade-villanueva, J. Echevarria, P. Chetchotisakd, J. Corral et al., Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study, The Lancet, vol.372, issue.9639, pp.372646-655, 2008.
DOI : 10.1016/S0140-6736(08)61081-8

J. Molina, J. Andrade-villanueva, J. Echevarria, P. Chetchotisakd, J. Corral et al., Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1

J. Lennox, E. Dejesus, A. Lazzarin, R. Pollard, J. Madruga et al., Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial, The Lancet, vol.374, issue.9692, pp.374796-806, 2009.
DOI : 10.1016/S0140-6736(09)60918-1

R. Landovitz, H. Ribaudo, and I. Ofotokun, Efficacy and Tolerability of Atazanavir, Raltegravir, or Darunavir with FTC/TDF: ACTG A5257. Abstract 85, Conference on Retroviruses and Opportunistic Infections, 2014.

. Objectif, Comparer l'efficacité virologique de différents schémas d'ARV instaurés lors de la PI VIH et déterminer les facteurs prédictifs d'échec virologique (EV) à 6 mois de traitement

P. Méthodes-de, C. Vih, and . De-rouen, Cinquante-cinq adultes traités dans les 3 mois suivant le diagnostic, entre 2003 et 2013 ont été inclus dans cette analyse rétrospective. L'EV était défini par la 1 ère charge virale VIH plasmatique (CV) ? 40 copies

F. and A. Rtv, sous 3TC-AZT-EFV. Ces 11 patients avaient une CV initiale moyenne = 4,3.10 6 copies/ml significativement plus élevée que celle des patients en succès virologique (p=0,03)

. Significativement-plus-bas, Leur CV était indétectable, en moyenne, à 14 mois de traitement Aucune molécule utilisée pour traiter ces 11 patients n'était touchée par la résistance ni sur le TGRA réalisé lors du diagnostic ni sur celui réalisé au moment de l'EV. Le dosage des ARV au moment de l'EV retrouvait une concentration diminuée d'au moins une molécule chez 2/11 patients. En analyse multivariée, aucun facteur prédictif d'EV (âge, sexe, mode de contamination, origine ethnique, sous-type viral